LRP5:在发育,疾病和治疗标中具有多方面的共同受体
1Department of Biology/Genetic and Molecular Biology Central Laboratory (GMCL), Jamoum University College, Umm Al-Qura University, Makkah 2203, Saudi Arabia.
Cells
|September 13, 2025
概括
低密度脂蛋白受体相关蛋白5 (LRP5) 对发育和疾病至关重要,影响骨,眼睛,脏和新陈代谢. 调节LRP5为各种疾病提供治疗潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 低密度脂蛋白受体相关蛋白5 (LRP5) 是一个关键的跨膜核受体.
- LRP5主要通过Wnt/β-catenin通路发送信号,但也通过非正规通路 (AKT/P21,TGF-β/Smad) 发送信号.
- LRP5中的突变会导致骨疾病,如骨质疏松症-伪骨质瘤综合征和高骨质量.
研究的目的:
- 审查LRP5在生理过程和疾病发病过程中的多方面的作用.
- 探索LRP5在各种器官系统的参与,包括骨,眼睛,脏和代谢.
- 突出LRP5的治疗潜力和需要有针对性的调制策略.
主要方法:
- 对LRP5功能和相关信号通路的文献综述.
- 分析LRP5在正常发育和病理条件中的作用.
- 检查针对LRP5.5的当前和新兴治疗策略.
主要成果:
- LRP5调节视网膜血管生成,血管完整性,功能,神经发育和脂质代谢.
- LRP5表现出双重作用,防止急性损伤,但通过纤维化和炎症促进慢性疾病.
- LRP5影响脂肪细胞分化,胰岛素敏感性和神经元可塑性.
结论:
- LRP5是一个关键的调节器,在多个器官系统中具有多种功能.
- 由于LRP5参与了保护性和有害性路径,因此需要特定于环境的治疗方法.
- 准LRP5为一系列疾病提供了有前途的治疗途径.
关键词:
对抗DKK-1的方法在LRP5中使用LRP5.没有信号通路.在Wnt/β-catenin中使用.血管新生是因为血管新生.抗硬化素的抗硬化素.癌症 癌症 癌症 癌症 癌症有纤维化的纤维化.脂质新陈代谢 脂质新陈代谢低密度脂蛋白受体相关的蛋白-5-5骨质疏松症是一种骨质疏松症.更多相关视频
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
14.4K
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
9.4K
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
Receptor Tyrosine Kinases
18.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.1K
Targets for Drug Action: Overview
10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
